Pediatrix Medical Group, Inc. $MD Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 19.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 494,381 shares of the company’s stock after selling 116,530 shares during the period. Pacer Advisors Inc.’s holdings in Pediatrix Medical Group were worth $10,575,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of MD. Invesco Ltd. raised its holdings in shares of Pediatrix Medical Group by 24.4% in the 4th quarter. Invesco Ltd. now owns 1,090,655 shares of the company’s stock valued at $23,329,000 after buying an additional 213,636 shares during the period. State of Tennessee Department of Treasury boosted its holdings in Pediatrix Medical Group by 2.8% during the 4th quarter. State of Tennessee Department of Treasury now owns 46,016 shares of the company’s stock valued at $984,000 after acquiring an additional 1,246 shares during the period. EP Wealth Advisors LLC purchased a new position in Pediatrix Medical Group during the 4th quarter valued at about $472,000. Mackenzie Financial Corp grew its position in Pediatrix Medical Group by 35.7% in the 4th quarter. Mackenzie Financial Corp now owns 55,150 shares of the company’s stock valued at $1,201,000 after acquiring an additional 14,502 shares in the last quarter. Finally, Empowered Funds LLC grew its position in Pediatrix Medical Group by 17.8% in the 4th quarter. Empowered Funds LLC now owns 622,380 shares of the company’s stock valued at $13,313,000 after acquiring an additional 93,833 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MD. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Friday, March 27th. Truist Financial raised their price objective on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, April 13th. Jefferies Financial Group restated a “buy” rating and issued a $27.00 price objective on shares of Pediatrix Medical Group in a report on Monday, April 20th. UBS Group upped their target price on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Finally, Mizuho set a $24.00 target price on shares of Pediatrix Medical Group in a report on Friday, May 8th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $22.50.

Insider Buying and Selling

In related news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.80% of the stock is owned by company insiders.

Pediatrix Medical Group Trading Up 0.1%

NYSE MD opened at $23.62 on Monday. Pediatrix Medical Group, Inc. has a 52 week low of $11.84 and a 52 week high of $24.99. The firm has a 50 day moving average of $22.67 and a two-hundred day moving average of $21.70. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $1.94 billion, a PE ratio of 11.47 and a beta of 0.69.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $476.20 million for the quarter, compared to analyst estimates of $465.83 million. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The company’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the business earned $0.33 EPS. As a group, research analysts expect that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.